Also approved acquisition of 19% stake in Swiss Parenterals
The Board of Eris Lifesciences at its meeting held on 14 March 2024 has approved the following:➢ Agreement to acquire the Branded Formulations businesses of Biocon Biologics pertaining to the Indian Territory to the extent and in the manner mentioned therein.
➢ Agreement to acquire 19% equity stake in Swiss Parenterals from the Promoters of the Company.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
